Additionally, all these studies share a common theme of reduction in body weight and improved insulin sensitivity among patients, confirming that these medications could be promising for patients with PCOS who exhibit similar clinical findings, including increased weight gain, dysmenorrhea, and an increased number of ovarian cysts. This evidence concerns the gene INS and polycystic ovary syndrome.